Literature DB >> 20558741

Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells.

Cheryl Habrukowich1, David K Han, Andrew Le, Karim Rezaul, Wei Pan, Mallika Ghosh, Zaiguo Li, Kimberly Dodge-Kafka, Xuejun Jiang, Robert Bittman, Timothy Hla.   

Abstract

Sphingolipid metabolites regulate cell fate by acting on specific cellular targets. Although the influence of sphingolipids in cellular signaling has been well recognized, the exact molecular targets and how these targets influence cellular signaling mechanisms remain poorly understood. Toward this goal, we used affinity chromatography coupled with proteomics technology and identified acidic leucine-rich nuclear phosphoprotein-32A (ANP32A), an inhibitor of protein phosphatase 2A (PP2A) as a direct target of sphingosine, N,N'-dimethyl sphingosine (DMS) and phytosphingosine but not dihydrosphingosine or sphingosine 1-phosphate. Treatment of human umbilical vein endothelial cells (HUVEC) with DMS, which is not phosphorylated by sphingosine kinases, led to the activation of PP2A activity. Suppression of ANP32A with siRNA enhanced basal and DMS-activated PP2A activity suggesting that the sphingoid base binds to and relieves the inhibitory action of ANP32A on the PP2A complex. Indeed, DMS relieved the ANP32A-mediated inhibition of PP2A enzyme complex in vitro. Interestingly, DMS treatment induced the p38 stress-activated protein kinase (SAPK) and expression of cyclooxygenase (COX)-2 transcript and protein. Knockdown of ANP32A expression further induced p38 SAPK and COX-2. These data identify ANP32A as a novel molecular target of sphingoid bases that regulates cellular signaling events and inflammatory gene expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558741      PMCID: PMC2930681          DOI: 10.1074/jbc.M110.147058

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry.

Authors:  D K Han; J Eng; H Zhou; R Aebersold
Journal:  Nat Biotechnol       Date:  2001-10       Impact factor: 54.908

2.  Sphingoid base synthesis requirement for endocytosis in Saccharomyces cerevisiae.

Authors:  B Zanolari; S Friant; K Funato; C Sütterlin; B J Stevenson; H Riezman
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

Review 3.  Lysophospholipids--receptor revelations.

Authors:  T Hla; M J Lee; N Ancellin; J H Paik; M J Kluk
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

4.  Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells.

Authors:  V E Nava; O Cuvillier; L C Edsall; K Kimura; S Milstien; E P Gelmann; S Spiegel
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

5.  Mutant analysis reveals complex regulation of sphingolipid long chain base phosphates and long chain bases during heat stress in yeast.

Authors:  Stacey R Ferguson-Yankey; Marek S Skrzypek; Robert L Lester; Robert C Dickson
Journal:  Yeast       Date:  2002-05       Impact factor: 3.239

Review 6.  Sphingosine in apoptosis signaling.

Authors:  Olivier Cuvillier
Journal:  Biochim Biophys Acta       Date:  2002-12-30

7.  A role for protein phosphatase-2A in p38 mitogen-activated protein kinase-mediated regulation of the c-Jun NH(2)-terminal kinase pathway in human neutrophils.

Authors:  Natalie J Avdi; Kenneth C Malcolm; Jerry A Nick; G Scott Worthen
Journal:  J Biol Chem       Date:  2002-08-16       Impact factor: 5.157

8.  Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway.

Authors:  Xuejun Jiang; Hyun-Eui Kim; Hongjun Shu; Yingming Zhao; Haichao Zhang; James Kofron; Jennifer Donnelly; Dave Burns; Shi-Chung Ng; Saul Rosenberg; Xiaodong Wang
Journal:  Science       Date:  2003-01-10       Impact factor: 47.728

9.  COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation.

Authors:  Mallika Ghosh; Haibin Wang; Youxi Ai; Elisa Romeo; James P Luyendyk; Jeffrey M Peters; Nigel Mackman; Sudhansu K Dey; Timothy Hla
Journal:  J Exp Med       Date:  2007-08-27       Impact factor: 14.307

10.  Protein ligands to HuR modulate its interaction with target mRNAs in vivo.

Authors:  C M Brennan; I E Gallouzi; J A Steitz
Journal:  J Cell Biol       Date:  2000-10-02       Impact factor: 10.539

View more
  23 in total

1.  Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.

Authors:  Patrick T Reilly; Yun Yu; Ali Hamiche; Lishun Wang
Journal:  Bioessays       Date:  2014-08-25       Impact factor: 4.345

2.  Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod).

Authors:  Salma Buddaseth; Wiebke Göttmann; Rainer Blasczyk; Trevor Huyton
Journal:  Cancer Biol Ther       Date:  2013-12-12       Impact factor: 4.742

Review 3.  Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease.

Authors:  Michael Voronkov; Steven P Braithwaite; Jeffry B Stock
Journal:  Future Med Chem       Date:  2011-05       Impact factor: 3.808

Review 4.  Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.

Authors:  Suriyan Ponnusamy; Marisa Meyers-Needham; Can E Senkal; Sahar A Saddoughi; David Sentelle; Shanmugam Panneer Selvam; Arelis Salas; Besim Ogretmen
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

5.  FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.

Authors:  Mei-Hong Li; Timothy Hla; Fernando Ferrer
Journal:  Pediatr Blood Cancer       Date:  2013-05-23       Impact factor: 3.167

Review 6.  Sphingolipid signaling in metabolic disorders.

Authors:  Timothy Hla; Andrew J Dannenberg
Journal:  Cell Metab       Date:  2012-09-13       Impact factor: 27.287

7.  Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Authors:  Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Steve Roof; Jason G Harb; Greg Ferenchak; Ann-Kathrin Eisfeld; James R Van Brocklyn; Roger Briesewitz; Sahar A Saddoughi; Kyosuke Nagata; Robert Bittman; Michael A Caligiuri; Omar Abdel-Wahab; Ross Levine; Ralph B Arlinghaus; Alfonso Quintas-Cardama; John M Goldman; Jane Apperley; Alistair Reid; Dragana Milojkovic; Mark T Ziolo; Guido Marcucci; Besim Ogretmen; Paolo Neviani; Danilo Perrotti
Journal:  Blood       Date:  2013-08-07       Impact factor: 22.113

Review 8.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Authors:  Jaya Sangodkar; Caroline C Farrington; Kimberly McClinch; Matthew D Galsky; David B Kastrinsky; Goutham Narla
Journal:  FEBS J       Date:  2015-11-14       Impact factor: 5.542

9.  Differential Splicing of ANP32A in Birds Alters Its Ability to Stimulate RNA Synthesis by Restricted Influenza Polymerase.

Authors:  Steven F Baker; Mitchell P Ledwith; Andrew Mehle
Journal:  Cell Rep       Date:  2018-09-04       Impact factor: 9.423

10.  Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs.

Authors:  Peter Kubiniok; Brendan T Finicle; Fanny Piffaretti; Alison N McCracken; Michael Perryman; Stephen Hanessian; Aimee L Edinger; Pierre Thibault
Journal:  Mol Cell Proteomics       Date:  2018-11-27       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.